Does omalizumab really benefit patients with severe asthma?, asks DTB

Omalizumab is an injectable treatment for people with severe, allergic asthma that is not controlled by standard therapies. But a lack of evidence to support use of the drug in this group of patients does not justify its high cost, says Drug and Therapeutics Bulletin (DTB) in its review this month.

Dr Ike Iheanacho, editor of DTB comments: “The annual cost of omalizumab ranges from around £3,000 to £20,000 excluding the cost of a healthcare professional preparing and giving the injections.

However, in the key published study that has assessed its effectiveness in patients with severe asthma, omalizumab provided, at best, only a marginal reduction in the rate of asthma exacerbations. There is simply not enough evidence to justify omalizumab’s hype as a wonder drug.”

DTB believes that omalizumab should only be used in the context of clinical trials that aim to provide information on its efficacy in preventing exacerbations, hospital admissions and oral corticosteroid use, as well as its cost-effectiveness.

Also in DTB this month:

When and how it is best to give combination therapy for early rheumatoid arthritis?

  • Around one per cent of adults in the UK have rheumatoid arthritis.
  • Early intervention can reduce long-term joint damage so, patients need to be seen early (preferably within 3 months of first being seen) by a rheumatologist for initiation of disease-modifying-anti-rheumatic drugs (DMARDs).
  • DTB looks at the use of DMARDs to assess whether they should be administered as sole therapy or in combination.  It also looks at when and how best to give combination therapy.

Contact Vicky Taylor on 0207 770 7567 / vicky.taylor@which.co.uk

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS app goes live with full rollout to all GP practices promised by July

NHS app goes live with full rollout to all GP practices promised by July

Patients across England can now download an NHS app that will allow them to book...

NICE recommends digital CBT for children with mild depression

NICE recommends digital CBT for children with mild depression

Children and young people with mild depression should have access to digital cognitive...

GPs taking early retirement triple in a decade as tax limits hit workforce

GPs taking early retirement triple in a decade as tax limits hit workforce

Numbers of GPs taking early retirement have tripled over the past decade as tighter...

BMA safety warning as pharmacists gain power to switch prescriptions

BMA safety warning as pharmacists gain power to switch prescriptions

Pharmacists are set to be granted emergency powers to alter patients' prescriptions...

GP funding could rise £60m through deals on QOF, networks and digital health

GP funding could rise £60m through deals on QOF, networks and digital health

GP leaders hope to trigger a 1% boost to practice funding from April - on top of...

GP trainees unfairly denied £20,000 golden hello payments, says BMA

GP trainees unfairly denied £20,000 golden hello payments, says BMA

Some GP trainees expecting £20,000 golden hellos for working in under-doctored areas...